Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 6, 2005, Pages 2260-2266

  Weigelt, John ^a   Itani, Kamal ^b   Stevens, Dennis ^c   Lau, William ^d   Dryden, Matthew ^e   Knirsch, Charles ^f,g  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Boise VA Medical Center   (United States)

^d St Francis Healthcare System of Hawaii   (United States)

^e ROYAL HAMPSHIRE COUNTY HOSPITAL   (United Kingdom)

^f Pfizer World Wide Medical   (United States)

^g PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEPHALOSPORIN; DICLOXACILLIN; FLUCLOXACILLIN; LINEZOLID; METICILLIN; NAFCILLIN; OXACILLIN; PENICILLIN DERIVATIVE; VANCOMYCIN;

ABSCESS; ADULT; ANAPHYLAXIS; ANEMIA; ARTICLE; BURN INFECTION; CELLULITIS; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIARRHEA; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTICENTER STUDY; NAUSEA; PHLEBITIS; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SKIN INFECTION; SKIN ULCER; SOFT TISSUE INFECTION; THROMBOCYTOPENIA; VOMITING;

ACETAMIDES; ADULT; AGED; ANTI-INFECTIVE AGENTS; FEMALE; HUMANS; INTERNATIONALITY; MALE; METHICILLIN RESISTANCE; MIDDLE AGED; OXAZOLIDINONES; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME; VANCOMYCIN;

EID: 19544369670     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.6.2260-2266.2005     Document Type: Article

References (48)

1. Archer, G. L. 1998. Staphylococcus aureus: a well-armed pathogen. Clin. Infect. Dis. 26:1179-1181.
2. Ballow, C. H., R. N. Jones, D. J. Biedenbach, and the North American ZAPS Research Group. 2002. A multicenter evaluation of linezolid antimicrobial activity in North America. Diagn. Microbiol. Infect. Dis. 43:75-83.
3. Birmingham, M. C., C. R. Rayner, A. K. Meagher, S. M. Flavin, D. H. Batts, and J. J. Schentag. 2003. Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program. Clin. Infect. Dis. 36:159-168.
4. Boyce, J. M., M. Landry, T. R. Deetz, and H. L. DuPont. 1981. Epidemiologic studies of an outbreak of nosocomial methicillin-resistant Staphylococcus aureus infections. Infect. Control 2:110-116.
5. Diekema, D. J., M. A. Pfaller, F. J. Schmitz, J. Smayevsky, J. Bell, R. N. Jones, M. Beach, and the SENTRY Participants Group. 2001. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific Region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin. Infect. Dis. 32(Suppl. 2):S114-S132.
6. Doern, G. V., R. N. Jones, M. A. Pfaller, K. C. Kugler, M. L. Beach, and the SENTRY Study Group (North America). 1999. Bacterial pathogens isolated from patients with skin and soft tissue infections: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997). Diagn. Microbiol. Infect. Dis. 34:65-72.
7. European Antimicrobial Resistance Surveillance System. 2002. EARSS annual report 2001. European Antimicrobial Resistance Surveillance System, Bilthoven, The Netherlands.
8. Fejfarová, V., A. Jirkovaská, J. Skibová, and V. Petkov. 2000. Pathogen resistance and other risk factors in the frequency of lower limb amputations in patients with the diabetic foot syndrome. Vnitr. Lek. 48:302-306.
9. File, T. M., and J. S. Tan. 1995. Treatment of skin and soft tissue infections. Am. J. Surg. 169(Suppl. 5A):27S-33S.
10. Fines, M., and R. Leclercq. 2000. Activity of linezolid against gram-positive cocci possessing genes conferring resistance to protein synthesis inhibitors. J. Antimicrob. Chemother. 45:797-802.
11. Food and Drug Administration. 1998. Guidance for industry: uncomplicated and complicated skin and skin structure infections - developing antimicrobial drugs for treatment. [Online.] http://www.fda.gov/cdcr/guidance/2566dft.pdf.
12. Gee, T., R. Ellis, G. Marshall, J. Andrews, J. Ashby, and R. Wise. 2001. Pharmacokinetics and tissue penetration of linezolid following multiple oral doses. Antimicrob. Agents Chemother. 45:1843-1846.
13. Gerson, S. L., S. L. Kaplan, J. B. Bruss, V. Le, F. M. Arellano, B. Hafkin, and D. J. Kuter. 2002. Hematologic effects of linezolid: summary of clinical experience. Antimicrob. Agents Chemother. 46:2723-2726.
14. Graffunder, E. M., and R. A. Venezia. 2002. Risk factors associated with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobials. J. Antimicrob. Chemother. 49:999-1005.
15. Hau, T. 2002. Efficacy and safety of linezolid in the treatment of skin and soft tissue infections. Eur. J. Clin. Microbiol. Infect. Dis. 21:491-498.
16. Holmberg, S. D., S. L. Solomon, and P. A. Blake. 1987. Health and economic impacts of antimicrobial resistance. Rev. Infect. Dis. 9:1065-1078.
17. Hospital Infections Program, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Public Health Service, and U.S. Department of Health and Human Services. 1999. National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1990-May 1999, issued June 1999. Am. J. Infect. Control 27:520-532.
18. Jones, M. E., J. A. Karlowsky, D. C. Draghi, C. Thornsberry, D. F. Sahm, and D. Nathwani. 2003. Epidemiology and antibiotic susceptibility of bacteria causing skin and soft tissue infections in the USA and Europe: a guide to appropriate antimicrobial therapy. Int. J. Antimicrob. Agents 22:406-419.
19. Kirby, J. T., A. H. Mutnick, R. N. Jones, D. J. Biedenbach, and M. A. Pfaller. 2002. Geographic variations in garenoxacin (BMS284756) activity tested against pathogens associated with skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (2000). Diagn. Microbiol. Infect. Dis. 43:303-309.
20. Kutscha-Lissberg, F., U. Hebler, G. Muhr, and M. Köller. 2003. Linezolid penetration into bone and joint tissues infected with methicillin-resistant staphylococci. Antimicrob. Agents Chemother. 47:3964-3966.
21. Lemeshow, S., D. Teres, J. Klar, J. S. Avrunin, S. H. Gehlbach, and J. Rapoport. 1993. Mortality probability models (MPM II) based on an international cohort of intensive care unit patients. JAMA 270:2478-2486.
22. Li, J. Z., R. J. Willke, B. E. Rittenhouse, and M. J. Rybak. 2003. Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin-resistant Staphylococci: results from a randomized clinical trial. Surg. Infect. 4:57-70.
23. Li, Z., R. J. Willke, L. A. Pinto, B. E. Rittenhouse, M. J. Rybak, A. M. Pleil, C. W. Crouch, B. Hafkin, and H. A. Glick. 2001. Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus species infections treated with linezolid vancomycin: a randomized, multicenter trial. Pharmacotherapy 21:263-274.
24. Locksley, R. M., M. L. Cohen, T. C. Quinn, L. S. Tompkins, M. B. Coyle, J. M. Kirihara, and G. W. Counts. 1982. Multiple antibiotic-resistant Staphylococcus aureus: introduction, transmission, and evolution of nosocomial infection. Ann. Intern. Med. 97:317-324.
25. Lodise, T. P., Jr., P. S. McKinnon, and M. Rybak. 2003. Prediction model to identify patients with Staphylococcus aureus bacteremia at risk for methicillin resistance. Infect. Control Hosp. Epidemiol. 24:655-661.
26. Levering, A. M., J. Zhang, G. C. Bannister, B. J. Lankester, J. H. Brown, G. Narendra, and A. P. MacGowan. 2002. Penetration of linezolid into bone, fat, muscle, and haematoma of patients undergoing routine hip replacement. J. Antimicrob. Chemother. 50:73-77.
27. Lucet, J. C., S. Chevret, I. Durand-Zaleski, C. Chastang, B. Regnier, and the Multicenter Study Group. 2003. Prevalence and risk factors for carriage of methicillin-resistant Staphylococcus aureus at admission to the intensive care unit: results of a multicenter study. Arch. Intern. Med. 163:181-188.
28. Mutnick, A. H., D. J. Biedenbach, J. D. Turnidge, and R. N. Jones. 2002. Spectrum and potency evaluation of a new oxazolidinone, linezolid: a report from the SENTRY Antimicrobial Surveillance Program, 1998-2000. Diagn. Microbiol. Infect. Dis. 43:65-73.
29. Naimi, T. S., K. H. LeDell, K. Como-Sabetti, S. M. Borchardt, D. J. Boxrud, J. Etienne, S. K. Johnson, F. Vandenesch, S. Fridkin, C. O'Boyle, R. N. Danila, and R. Lynfield. 2003. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 290:2976-2984.
30. Nathwani, D. 2003. Impact of methicillin-resistant Staphylococcus aureus infections on key health economic outcomes: does reducing the length of hospital stay matter? J. Antimicrob. Chemother. 51(Suppl. S2):ii37-ii44.
31. Nichols, R. L. 1999. Optimal treatment of complicated skin and skin structure infections. J. Antimicrob. Chemother. 44:19-23.
32. Nichols, R. L., and S. Florman. 2001. Clinical presentations of soft-tissue infections and surgical site infections. Clin. Infect. Dis. 33(Suppl. 2):S84-S93.
33. Noskin, G. A. 2001. Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: emerging problems and new prospects for management. Ann. Acad. Med. Sing. 30:320-331.
34. Rana, B., I. Butcher, P. Grigoris, C. Murnaghan, R. A. Seaton, and C. M. Tobin. 2002. Linezolid penetration into osteo-articular tissues. J. Antimicrob. Chemother. 50:747-750.
35. Rello, J., A. Torres, M. Ricart, J. Valles, J. Gonzalez, A. Artigas, and R. Rodriguez-Roisin. 1994. Ventilator-associated pneumonia by Staphylococcus aureus. Am. J. Respir. Crit. Care Med. 150:1545-1549.
36. Rennie, R. P., R. N. Jones, A. H. Mutnick, and the SENTRY Program Study Group (North America). 2003. Occurrence and antimicrobial susceptibility patterns of pathogens isolated from skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 2000). Diagn. Microbiol. Infect. Dis. 45:287-293.
37. Shinabarger, D. L., K. R. Marotti, R. W. Murray, A. H. Lin, E. P. Melchior, S. M. Swaney, D. S. Dunyak, W. F. Demyan, and J. M. Buysse. 1997. Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions. Antimicrob. Agents Chemother. 41:2132-2136.
38. Slatter, J. G., D. J. Stalker, K. L. Feenstra, I. R. Welshman, J. B. Bruss, J. P. Sams, M. G. Johnson, P. E. Sanders, M. J. Hauer, P. E. Fagerness, R. P. Stryd, G. W. Peng, and E. M. Shobe. 2001. Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of linezolid to healthy human subjects. Drug Metab. Dispos. 29:1136-1145.
39. Solomkin, J. S., H. S. Bjornson, M. Cainzos, E. P. Dellinger, L. Dominioni, R. Eidus, E. Faist, D. Leaper, J. T. Lee, P. A. Lipsett, L. Napolitano, C. L. Nelson, R. G. Sawyer, J. Weigelt, and S. E. Wilson. 2004. A consensus statement on empiric therapy for suspected gram-positive infections in surgical patients. Am. J. Surg. 187:134-145.
40. Stevens, D. L., D. Herr, H. Lampiris, J. L. Hunt, D. H. Batts, and B. Hafkin. 2002. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin. Infect. Dis. 34:1481-1490.
41. Stevens, D. L., L. G. Smith, J. B. Bruss, M. A. McConnell-Martin, S. E. Duvall, W. M. Todd, and B. Hafkin for the Linezolid Skin and Soft Tissue Infectious Study Group. 2000. Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrob. Agents Chemother. 44:3408-3413.
42. Swartz, M. N. 1994. Hospital-acquired infections: diseases with increasingly limited therapies. Proc. Natl. Acad. Sci. USA 91:2420-2427.
43. Tobin, C. M., J. M. Darville, A. H. Thomson, G. Sweeney, J. F. Wilson, A. P. MacGowan, and L. O. White. 2002. Vancomycin therapeutic drug monitoring: is there a consensus view? The results of a UK National External Quality Assessment Scheme (UK NEQAS) for Antibiotic Assays questionnaire. J. Antimicrob. Chemother. 50:713-718.
44. Weigelt, J., H. M. Kaafarani, K. M. Itani, and R. N. Swanson. 2004. Linezolid eradicates MRSA better than vancomycin from surgical-site infections. Am. J. Surg. 188:760-766.
45. Welshman, I. R., T. A. Sisson, G. L. Jungbluth, D. J. Stalker, and N. K. Hopkins. 2001. Linezolid absolute bioavailability and the effect of food on oral bioavailability. Biopharm. Drug Dispos. 22:91-97.
46. Wilhelm, M. P., and L. Estes. 1999. Symposium on antimicrobial agents. Part XII. Vancomycin. Mayo Clin. Proc. 74:928-935.
47. Wilson, S. E. 2001. Clinical trial results with linezolid, an oxazolidinone, in the treatment of soft tissue and postoperative gram-positive infections. Surg. Infect. 2:25-35.
48. Wilson, S. E., J. S. Solomkin, V. Le, S. K. Cammarata, and J. B. Bruss. 2003. A severity score for complicated skin and soft tissue infections derived from phase III studies of linezolid. Am. J. Surg. 185:369-375.